Understanding the transition from alternative medicine to mainstream science: The homocysteine theory of heart disease and the crucial role of effective mentoring

Medical Hypotheses

Volumn 61, Issue 3, 2003, Pages 340-345

  Podell, Richard N ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; GAMMA LINOLENIC ACID; HOMOCYSTEINE;

ALTERNATIVE MEDICINE; ATHEROGENESIS; BLOOD ANALYSIS; CARDIOLOGY; CARDIOVASCULAR RISK; DIABETIC NEUROPATHY; HEALTH CARE; HEALTH CARE POLICY; HEART DISEASE; HEART INFARCTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LABORATORY TEST; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; SCIENCE;

EID: 0041910828     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(02)00417-6     Document Type: Article

References (60)

1. Fontanarosa P., Lundberg G. Alternative medicine meets science. JAMA 1998; 280: 1618-1629.
2. Angell M., Kassirer J. Alternative medicine - the risk of untested and unregulated remedies. N Engl J Med 1998; 229: 839-841.
3. McKully K. Vascular pathology of homocysteinemia: implications for the pathogenesis. Am J Pathol 1969; 56: 111-128.
4. McCully K. S., Wilson R. B. Homocysteine theory of arteriosclerosis. Atherosclerosis 1975; 22: 215-227.
5. McCully K. S. The Homocysteine Revolution: Medicine For the New Millennium. Los Angeles: Keats, 1999.
6. Wilcken D. E. L., Wilcken B. The pathogenesis of coronary artery disease: a possible role for methionine metabolism. J Clin Invest 1976; 57: 1079-1082.
7. Boushey C., Beresfod S., Omenn G. et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995; 274: 1049-1057.
8. Stampfer M., Malinow R., Willett W. et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992; 268: 877-881.
9. Eikelbloom J., Lonn E., Genest J. et al. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Int Med 1999; 131: 363-375.
10. Kilmer McCully, personal communication, December, 1999.
11. Irwin Rosenberg, personal communication, December, 1999.
12. Pauling L. Orthomolecular psychiatry. Science 1968; 160: 265-271.
13. Herbert V., Barrett S. Vitamins and 'Health' Foods: The Great American Hustle. Philadelphia: George F. Stickley, 1981.
14. Brattstrom L., Hardebo J., Hultberg B. Moderate homocysteinemia-a possible risk factor for arteriosclerotic cerebrovascular disease. Stroke 1999; 84(15): 1012-1016.
15. Brattstrom L., Hultberg B., Hardebo J. Folic acid responsive postmenopausal homocysteinemia. Metabolism 1985; 34: 1073-1077.
16. Isrealesson B., Brattstrom L., Hultberg B. Atherosclerosis 1988; 71: 227-233.
17. Brattstrom L., Isrealsson B., Hultberg B. Plasma homocysteine and methionine tolerance in early-onset vascular disease. Haemostasis 1989; 19(suppl.): 35-44.
18. Malinow M., Kang S., Taylor L. et al. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation 1989; 79: 1180-1188.
19. James Finkelstein, personal communication, January 2000; Jacob Selhub, Ph.D., personal communication, January 2000; Donald Jacobsen, Ph.D., personal communication, December, 1999.
20. James Finkelstein, personal communication, January 2000; Jacob Selhub, Ph.D., personal communication, January 2000; Donald Jacobsen, Ph.D., personal communication, December, 1999.
21. James Finkelstein, personal communication, January 2000; Jacob Selhub, Ph.D., personal communication, January 2000; Donald Jacobsen, Ph.D., personal communication, December, 1999.
22. Malinow M., Bardana E., Pirofsky B. et al. Systemic lupus erythematousus-like syndrome in monkeys fed alfalfa sprouts: role of a nonprotein amino acid. Science 1982; 216: 415-417.
23. Boers G., Smals A., Trijbels F. et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985; 313: 709-715.
24. Boers G. Carriership for homocystinuria in juvenile vascular disease. Haemostasis 1989; 19(suppl. 1): 29-34.
25. Olszewski A., Szostak W. Homocysteine content of plasma proteins in ischemic heart disease. Atherosclerosis 1988; 69: 109-113.
26. Olszewski A., Szostak W., Bialkowska M., Rudnicki S., McCully K. Reduction of plasma lipid and homocysteine levels by pyridoxine, folate, cobalamin, choline, riboflavin and aroxerutin in atherosclerosis. Atherosclerosis 1989; 75: 1-6.
27. Araki A., Sako Y., Fukushima Y. et al. Plasma sulfhydryl-containing amino acids in patient with cerebral refraction and in hypertensive subjects. Athersoclerosis 1989; 79: 139-146.
28. Ueland P., Refsum H. Plasma homocysteine, a risk factor for premature vascular disease. Plasma levels in health persons; during pathologic conditions and drug therapy. Nord Med 1980; 104: 293-298.
29. Wilcken D., Dudman N. Mechanisms of thrombogenesis and accelerated atherogenesis in homocysteinaemia. Haemostasis 1989; 19(suppl. 1): 14-23.
30. Malinow M.R., personal communication, December, 1999.
31. Malinow M. R. Hyperhomocyst(e)inemia: a common and easily reversible risk factor for occlusive atherosclerosis. Circulation 1990; 81: 2004-2006.
32. Malinow M., Sexton G., Averbuch M. et al. Homocyst(e)inemia in daily practice: levels in coronary artery disease. Coron Artery Dis 1990; 1: 215-220.
33. Genest J., McNamara J., Malinow M. Prevalence of familial hyperhomocyst(e)inemia in men with premature coronary artery disease. Arterioscler Thromb 1991; 11: 1129-1136.
34. Coull B., Malinow M. M., Beamer N. et al. Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke. Stroke 1990; 21: 572-576.
35. Molgaard J., Malinow M., Lassvik C. Hyperhomocyst(e)inemia. J Int Med 1992; 231: 273-279.
36. von Eckardstein A., Malinow M., Upson B. et al. Effects of age, lipoproteins, and hemostatic parameters on the role of homocyst(e)inemia as a cardiovascular risk factor in men. Arterioscerl Thromb 1994; 14: 460-464.
37. Verhoef P., Hennekens C., Malinow M. et al. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke 1994; 25: 1924-1930.
38. Malinow M., Nieto F., Szklo M. et al. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults: the atherosclerosis risk in communities study. Circulation 1993; 87: 1107-1113.
39. Meir Stampfer, personal communication, January 2000.
40. Jacobsen D., Gatautis V., Green R. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma. Clin Chem 1994; 40: 873-881.
41. Robinson K., Gupta A., Dennis V. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996; 94: 2742-2748.
42. Killian Robinson, personal communication, December, 1999.
43. Selhub J., Jacques P., Wilson P., Rush D., Rosenberg I. et al. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270: 2693-2698.
44. Selhab J., Jacques P., Bostom A. et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Eng J Med 1995; 332: 286-291.
45. Clarke R., Daly L., Robinson K. et al. Hyperhomo//cysteinemia. N Engl J Med 1991; 324: 1149-1155.
46. Brattstrom L., Lindgren A., Israelsson B. et al. Hyperhomocysteinemia in stroke. Eur J Clin Invest 1992; 22: 214-221.
47. Dudman N., Wilcken D. E. L., Wang J. et al. Disordered methionine/homocysteine metabolism in premature vascular disease. Arterioscler Thromb 1992; 13: 1253-1260.
48. Ubbink J., Vermaak W., Bennett J. et al. The prevalence of homocysteinemia and hypercholesterolemia in angiographically defined coronary heart disease. Klin Wochenschr 1991; 69: 527-534.
49. Arnesen E., Refsum H., Bona K., et al. The Tromso study: a population based prospective study of serum total homocysteine and coronary heart disease (Abstr No. 295). In: 3rd International Conference on Preventive Cardiology, 1993.
50. Nygard O., Vollset S., Refsum H. et al. Total plasma homocysteine and cardiovascular risk profile: the Hordaland homocysteine study. JAMA 1995; 274: 1526-1533.
51. Jamal G., Carmicahel H. The effect of γ-linolenic acid on human diabetic peripheral neuropathy a double blind placebo-controlled trial. Diabetes Med 1990; 7: 319-323.
52. Jamal G. The use of γ linolenic acid in the prevention and treatment of diabetic neuropathy. Diabetes Med 1994; 11: 145-149.
53. Horrobin D. Fatty acid metabolism in health and disease: the role of delta-6 desaturase. Am J Clin Nutr 1993; 57(suppl.): 732S-737S.
54. Horrobin D. The roles of essential fatty acids in the development of diabetic neuropathy and other complications of diabetes. Prostaglandins Leukot Essent Fatty Acids Rev 1998; 31: 181-197.
55. Tomlinson D., Robinson J., Compton A., Keen P. Essential fatty acid treatment effects on nerve conduction polyol pathways and axonal transport in streptozotocin diabetic rats. Diabetologia 1989; 32: 655-659.
56. Horrobin D. Essential fatty acids in the management of impaired nerve function in diabetes. Diabetes 1997; 46(suppl. 2): S90-S93.
57. Arisaka M., Arisaka O., Fukuda et al. Prostaglandin metabolism in children with diabetes mellitus. J Pediatr Gastroenterol Nutr 1986; 5: 878-882.
58. Mercun O., Peluffo R., Brenner R. Depression of microsomal desaturation of linoleic to γ-linolenic acid in the alloxan diabetic rat. Biochem Biophys Acta 1966; 116: 409-411.
59. Julu P. Essential fatty acids prevent slowed nerve conduction in streptozotocin diabetic rates. J Diabetes Complications 1988; 2: 285-288.
60. Keen H., Payan J., Allawi J. et al. Treatment of diabetic neuropathy with γ-linolenic acid. Diabetes Care 1993; 16: 8-14.